Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT06756217

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

Led by Ruijin Hospital · Updated on 2025-01-01

40

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.

CONDITIONS

Official Title

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical stage IB to IIIA (AJCC/UICC 8th Edition) before treatment
  • Resectable lung cancer confirmed by an experienced surgeon
  • Histologically confirmed primary non-small cell lung cancer
  • Men and women aged 18 to 75 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Expected survival of at least 6 months
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Diagnosis other than non-small cell lung cancer
  • Lung cancer that cannot be surgically removed or has distant metastasis
  • Previous cancers except certain skin and in situ cancers unless complete remission was achieved at least 2 years ago with no further therapy needed
  • Active or past autoimmune diseases or history requiring systemic steroids or immunosuppressants
  • Immunodeficiency conditions such as HIV or active hepatitis B or C
  • Uncontrolled diabetes or fasting blood glucose higher than 11.0 mmol/L
  • Women who are pregnant or breastfeeding
  • History of severe heart disease, severe bone marrow suppression, or severe liver or kidney failure
  • History of organ or stem cell transplantation
  • Any medical or psychological condition preventing study completion or understanding of study information

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025

Actively Recruiting

Loading map...

Research Team

H

Hecheng Li, MD, PHD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC | DecenTrialz